Crystal Structure of Human Thymidine Phosphorylase in Complex with a Small Molecule Inhibitor

Structure

Volumn 12, Issue 1, 2004, Pages 75-84

  Norman, Richard A ^a   Barry, Simon T ^a   Bate, Michael ^a   Breed, Jason ^a   Colls, Jeremy G ^a   Ernill, Richard J ^a   Luke, Richard W A ^a   Minshull, Claire A ^a   McAlister, Mark S B ^a   McCall, Eileen J ^a   McMiken, Helen H J ^a   Paterson, Dougie S ^a   Timms, David ^a   Tucker, Julie A ^a   Pauptit, Richard A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 6 [1 (2 IMINOPYRROLIDINYL)METHYL]URACIL; ANTINEOPLASTIC AGENT; CHLORIDE; PHOSPHORYLASE; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PYRIMIDINE NUCLEOTIDE; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; URACIL DERIVATIVE;

ARTICLE; BINDING AFFINITY; CATALYSIS; COMPUTER MODEL; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; MOLECULE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; VALIDATION PROCESS;

EID: 1642559369     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.str.2003.11.018     Document Type: Article

References (54)

1. Albert A., Serjeant E.P. Ionization Constants of Acids and Bases. A Laboratory Manual. 1962;Methuen and Co. Ltd, London.
2. Asai K., Nakanishi K., Isobe I., Eksioglu Y.Z., Hirano A., Hama K., Miyamoto T., Kato T. Neurotrophic action of gliostatin on cortical neurons. Identity of gliostatin and platelet-derived endothelial cell growth factor. J. Biol. Chem. 267:1992;20311-20316.
3. CCP4 Collaborative Computational Project 4) The CCP4 suite. programs for protein crystallography Acta Crystallogr. D. 50:1994;760-763.
4. Cole C., Reigan P., Gbaj A., Edwards P.N., Douglas K.T., Stratford I.J., Freeman S., Jaffar M. Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives. inhibitors of the angiogenic enzyme thymidine phosphorylase J. Med. Chem. 46:2003;207-209.
5. Creamer D., Jaggar R., Allen M., Bicknell R., Barker J. Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br. J. Dermatol. 137:1997;851-855.
6. DeLano W.L. The PyMOL Molecular Graphics System. 2002;DeLano Scientific, San Carlos, CA.
7. Desgranges C., Razaka G., Rabaud M., Bricaud H. Catabolism of thymidine in human blood platelets. purification and properties of thymidine phosphorylase Biochim. Biophys. Acta. 654:1981;211-218.
8. Eldridge M.D., Murray C.W., Auton T.R., Paolini G.V., Mee R.P., Murray C.W. Empirical scoring functions.1. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput. Aided Mol. Des. 11:1997;425-445.
9. Esnouf R.M. Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. Acta Crystallogr. D. 55:1999;938-940.
10. Fox S.B., Westwood M., Moghaddam A., Comley M., Turley H., Whitehouse R.M., Bicknell R., Gatter K.C., Harris A.L. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br. J. Cancer. 73:1996;275-280.
11. Fukushima M., Suzuki N., Emura T., Yano S., Kazuno H., Tada Y., Yamada Y., Asao T. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′- deoxyribonucleosides. Biochem. Pharmacol. 59:2000;1227-1236.
12. Grant J.A., Pickup B.T., Nicholls A. A smooth permittivity function for Poisson-Boltzmann solvation methods. J. Comput. Chem. 22:2001;608-640.
13. Halgren T.A., Halgren T.A. Merck molecular force field.1. Basis, form, scope, parameterization, and performance of mmff94. J. Comput. Chem. 17:1996;490-519.
14. Hooft R.W.W., Sander C., Vriend G., Hooft R.W.W. Positioning hydrogen atoms by optimizing hydrogen-bond networks in protein structures. Proteins. 26:1996;363-376.
15. Ignatescu M.C., Gharehbaghi-Schnell E., Hassan A., Rezaie-Majd S., Korschineck I., Schleef R.R., Glogar H.D., Lang I.M. Expression of the angiogenic protein, platelet-derived endothelial cell growth factor, in coronary atherosclerotic plaques. in vivo correlation of lesional microvessel density and constrictive vascular remodeling Arterioscler. Thromb. Vasc. Biol. 19:1999;2340-2347.
16. Kraut A., Yamada E.W. Cytoplasmic uridine phosphoryaseft liver. Characterization and kinetics. J. Biol. Chem. 246:1971;2021-2030.
17. Krenitsky T.A. Pentosyl transfer mechanisms of the mammalian nucleoside phosphorylases. J. Biol. Chem. 243:1968;2871-2875.
18. Krenitsky T.A., Tuttle J.V. Correlation of substrate-stabilization patterns with proposed mechanisms for three nucleoside phosphorylases. Biochim. Biophys. Acta. 703:1982;247-249.
19. Krenitsky T.A., Mellors J.W., Barclay R.K. Pyrimidine nucleosidases. their classification and relationship to uric acid ribonucleoside phosphorylase J. Biol. Chem. 240:1965;1281-1286.
20. Krenitsky T.A., Koszalka G.W., Tuttle J.V. Purine nucleoside synthesis, an efficient method employing nucleoside phosphorylases. Biochemistry. 20:1981;3615-3621.
21. Langen P., Etzold G., Barwolff D., Preussel B. Inhibition of thymidine phosphorylase by 6-aminothymine and derivatives of 6-aminouracil. Biochem. Pharmacol. 16:1967;1833-1837.
22. Laskowski R.A., Moss D.S., Thornton J.M. Main-chain bond lengths and bond angles in protein structures. J. Mol. Biol. 231:1993;1049-1067.
23. Leslie, A.G.W. (1992). Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography No. 26.
24. Levitt D.G. A new software routine that automates the fitting of protein X-ray crystallographic electron-density maps. Acta Crystallogr. D. 57:2001;7-9.
25. Mackerell A.D., Bashford D., Bellott M., Dunbrack R.L., Evanseck J.D., Field M.J., Fischer S., Gao J., Guo H., Ha S.et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B. 102:1998;3586-3616.
26. Maeda K., Chung Y.S., Ogawa Y., Takatsuka S., Kang S.M., Ogawa M., Sawada T., Onoda N., Kato Y., Sowa M. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br. J. Cancer. 73:1996;884-888.
27. Matsushita S., Nitanda T., Furukawa T., Sumizawa T., Tani A., Nishimoto K., Akiba S., Miyadera K., Fukushima M., Yamada Y.et al. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res. 59:1999;1911-1916.
28. Merrit E.A., Murphy M.E.P. Raster 3D version 2.0 - a program for photorealistic molecular graphics. Acta Crystallogr. D. 50:2003;869-873.
29. Miwa M., Ura M., Nishida M., Sawada N., Ishikawa T., Mori K., Shimma N., Umeda I., Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer. 34:1998;1274-1281.
30. Miyadera K., Sumizawa T., Haraguchi M., Yoshida H., Konstanty W., Yamada Y., Akiyama S. Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res. 55:1995;1687-1690.
31. Miyazono K., Okabe T., Urabe A., Takaku F., Heldin C.H. Purification and properties of an endothelial cell growth factor from human platelets. J. Biol. Chem. 262:1987;4098-4103.
32. Mizutani Y., Okada Y., Yoshida O. Expression of platelet-derived endothelial cell growth factor in bladder carcinoma. Cancer. 79:1997;1190-1194.
33. Moghaddam A., Bicknell R. Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry. 31:1992;12141-12146.
34. Moghaddam A., Zhang H.T., Fan T.P., Hu D.E., Lees V.C., Turley H., Fox S.B., Gatter K.C., Harris A.L., Bicknell R. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc. Natl. Acad. Sci. USA. 92:1995;998-1002.
35. O'Brien T., Cranston D., Fuggle S., Bicknell R., Harris A.L. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res. 55:1995;510-513.
36. O'Brien T.S., Fox S.B., Dickinson A.J., Turley H., Westwood M., Moghaddam A., Gatter K.C., Bicknell R., Harris A.L. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res. 56:1996;4799-4804.
37. Patterson A.V., Zhang H., Moghaddam A., Bicknell R., Talbot D.C., Stratford I.J., Harris A.L. Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br. J. Cancer. 72:1995;669-675.
38. Pauly J.L., Schuller M.G., Zelcer A.A., Kirss T.A., Gore S.S., Germain M.J. Identification and comparative analysis of thymidine phosphorylase in the plasma of healthy subjects and cancer patients. J. Natl. Cancer Inst. 58:1977;1587-1590.
39. Price M.L., Guida W.C., Jackson T.E., Nydick J.A., Gladstone P.L., Juarez J.C., Donate F., Ternansky R.J. Design of novel N-(2,4-dioxo-1,2,3,4- tetrahydro-thieno[3,2-d]pyrimidin-7-yl)-guanidines as thymidine phosphorylase inhibitors, and flexible docking to a homology model. Bioorg. Med. Chem. Lett. 13:2003;107-110.
40. Pugmire M.J., Ealick S.E. The crystal structure of pyrimidine nucleoside phosphorylase in a closed conformation. Structure. 6:1998;1467-1479.
41. Pugmire M.J., Ealick S.E. Structural analyses reveal two distinct families of nucleoside phosphorylases. Biochem. J. 361:2002;1-25.
42. Pugmire M.J., Cook W.J., Jasanoff A., Walter M.R., Ealick S.E. Structural and theoretical studies suggest domain movement produces an active conformation of thymidine phosphorylase. J. Mol. Biol. 281:1998;285-299.
43. Reynolds K., Farzaneh F., Collins W.P., Campbell S., Bourne T.H., Lawton F., Moghaddam A., Harris A.L., Bicknell R. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J. Natl. Cancer Inst. 86:1994;1234-1238.
44. Schwartz M. Thymidine phosphorylase from Escherichia coli. Properties and kinetics. Eur. J. Biochem. 21:1971;191-198.
45. Schwartz M. Thymidine phosphorylase from Escherichia coli. Methods Enzymol. 51:1978;442-445.
46. Spraggon M., Stuart D., Ponting C., Finnis C., Sleep D., Jones Y. Crystallization and x-ray diffraction study of recombinant platelet-derived endothelial cell growth factor. J. Mol. Biol. 234:1993;879-880.
47. Sumizawa T., Furukawa T., Haraguchi M., Yoshimura A., Takeyasu A., Ishizawa M., Yamada Y., Akiyama S. Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J. Biochem. (Tokyo). 114:1993;9-14.
48. Takebayashi Y., Akiyama S., Akiba S., Yamada K., Miyadera K., Sumizawa T., Yamada Y., Murata F., Aikou T. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J. Natl. Cancer Inst. 88:1996;1110-1117. a.
49. Takebayashi Y., Miyadera K., Akiyama S., Hokita S., Yamada K., Akiba S., Yamada Y., Sumizawa T., Aikou T. Expression of thymidine phosphorylase in human gastric carcinoma. Jpn. J. Cancer Res. 87:1996;288-295. b.
50. Takeuchi M., Otsuka T., Matsui N., Asai K., Hirano T., Moriyama A., Isobe I., Eksioglu Y.Z., Matsukawa K., Kato T. Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid synovium. Arthritis Rheum. 37:1994;662-672.
51. Thomas M.B., Hoff P.M., Carter S., Bland G., Lassere Y., Wolff R., Xiong H., Hayakawa T., Abbruzzese J. A dose-finding, safety and pharmacokinetics study of TAS-102, an antitumor/antiangiogenic agent given orally on a once-daily schedule for five-days every three weeks in patients with solid tumors. Proc. Am. Assoc. Cancer Res. 43:2002;554.
52. Walter M.R., Cook W.J., Cole L.B., Short S.A., Koszalka G.W., Krenitsky T.A., Ealick S.E. Three-dimensional structure of thymidine phosphorylase from Escherichia coli at 2.8Å resolution. J. Biol. Chem. 265:1990;14016-14022.
53. Zimmerman M., Seidenberg J. Deoxyribosyl transfer. I. Thymidine phosphorylase and nucleoside deoxyribosyltransferase in normal and malignant tissues. J. Biol. Chem. 239:1964;2618-2621. a.
54. Zimmerman M., Seidenberg J. Deoxyribosyl transfer. II. Nucleoside. pyrimidine deoxyribosyltransferase activity of three partially purified thymidine phosphorylases J. Biol. Chem. 239:1964;2622-2627. b.